Is REPCF or ORCC a better dividend investment in 2026?

REPCF currently yields 2000000.00% with a 5% 5-year dividend growth rate. ORCC yields 9.79% with 5% growth. The better choice depends on your goal: REPCF offers higher current income.

What is the dividend yield difference between REPCF and ORCC?

REPCF has a forward dividend yield of 2000000.00% ($2.00/share annually). ORCC yields 9.79% ($1.32/share annually). The yield gap is 1999990.21 percentage points.

Home › Compare › REPCF vs ORCC

REPCF vs ORCC: Dividend Comparison 2026

REPCF yields 2000000.00% · ORCC yields 9.79%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 REPCF wins by $4.879226400974806e+39M in total portfolio value

INVESTMENT

TIME HORIZON10 years

REPCF

● Live price

2000000.00%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.879226400974806e+39M

Annual income

$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00

Full REPCF calculator →

ORCC

● Live price

9.79%

Share price

$13.48

Annual div

$1.32

5Y div CAGR

-50%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$21.4K

Annual income

$1.04

Full ORCC calculator →

Portfolio growth — REPCF vs ORCC

📍 REPCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	REPCF	ORCC
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, REPCF + ORCC cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

REPCF pays

ORCC pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

REPCF

Annual income on $10K today (after 15% tax)

$170,000,000.00/yr

After 10yr DRIP, annual income (after tax)

$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr

ORCC

Annual income on $10K today (after 15% tax)

$832.34/yr

After 10yr DRIP, annual income (after tax)

$0.88/yr

At 15% tax rate, REPCF beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of REPCF + ORCC for your $10,000?

REPCF: 50%ORCC: 50%

100% ORCC50/50100% REPCF

Portfolio after 10yr

$2.439613200487403e+39M

Annual income

$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr

Blended yield

99.99%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

REPCF

No analyst data

Altman Z

-4668.2

Piotroski

2/9

ORCC

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$16.00

+18.7% upside vs current

Range: $16.00 — $16.00

Altman Z

0.5

Piotroski

5/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

REPCF buys

ORCC buys

No recent congressional trades found for REPCF or ORCC in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricREPCFORCC

Forward yield	2000000.00% ✓	9.79%
Annual dividend / share	$2.00 ✓	$1.32
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0% ✓	-50%
Portfolio after 10y	$4.879226400974806e+39M	$21.4K ✓
Annual income after 10y	$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00 ✓	$1.04
Total dividends collected	$4.879195005460081e+39M ✓	$1.0K
Payment frequency	quarterly	quarterly
Sector	Stock	BDC

Year-by-year: REPCF vs ORCC ($10,000, DRIP)

Year	REPCF Portfolio	REPCF Income/yr	ORCC Portfolio	ORCC Income/yr	Gap
1← crossover	$200,010,700	$200,000,000.00	$11,190	$489.61	+$200.00M → REPCF
2	$3,738,731,768,458	$3,738,517,757,009.35	$12,229	$256.01	+$3738731.76M → REPCF
3	$65,315,062,866,930,490	$65,311,062,423,938,240.00	$13,216	$130.74	+$65315062866.92M → REPCF
4	$1,066,400,830,062,625,000,000	$1,066,330,942,945,357,500,000.00	$14,207	$66.02	+$1066400830062625.00M → REPCF
5	$16,272,182,796,453,826,000,000,000	$16,271,041,747,565,660,000,000,000.00	$15,234	$33.17	+$16272182796453826560.00M → REPCF
6	$232,054,240,113,661,900,000,000,000,000	$232,036,828,878,069,680,000,000,000,000.00	$16,317	$16.62	+$2.3205424011366188e+23M → REPCF
7	$3,092,799,066,104,688,500,000,000,000,000,000	$3,092,550,768,067,767,400,000,000,000,000,000.00	$17,468	$8.32	+$3.0927990661046884e+27M → REPCF
8	$38,524,105,697,352,694,000,000,000,000,000,000,000	$38,520,796,402,351,967,000,000,000,000,000,000,000.00	$18,695	$4.16	+$3.8524105697352695e+31M → REPCF
9	$448,468,826,014,798,700,000,000,000,000,000,000,000,000	$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00	$20,006	$2.08	+$4.484688260147987e+35M → REPCF
10	$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000	$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00	$21,407	$1.04	+$4.879226400974806e+39M → REPCF

REPCF vs ORCC: Complete Analysis 2026

REPCF — Stock

RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01 for the treatment of chronic tendinosis; RCS-01 to treat aging and sun damaged skin; and RCH-01 for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.

Full REPCF Calculator →

ORCC — BDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →

📬

Get this REPCF vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

REPCF vs SCHD REPCF vs JEPI REPCF vs O REPCF vs KO REPCF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.